Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.126
Neutral
RSI(14)
60.194
Neutral
STOCH(KDJ)(9,3,3)
35.231
Sell
ATR(14)
3.104
High Vlolatility
CCI(14)
7.648
Neutral
Williams %R
44.574
Buy
TRIX(12,20)
0.736
Sell
StochRSI(14)
0.000
Oversold
Merck & Co Inc
MRK99.720USD
-1.170-1.16%
Close 12/05, 16:00（ET）Quotes delayed by 15 min
248.04BMarket Cap
13.03P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Merck & Co Inc
Currency: USD Updated: 2025-12-05Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Merck & Co Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
30
analysts
Buy
Current Rating
104.088
Target Price
+4.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Merck & Co Inc Highlights
StrengthsRisks
Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 64.17B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 46.40%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 46.40%.
Undervalued
The company’s latest PE is 13.16, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.02B shares, decreasing 2.22% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 46.76K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.02.
Financial Health
Currency: USD Updated: 2025-12-05The company's current financial score is 8.54, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.28B, representing a year-over-year increase of 3.72%, while its net profit experienced a year-over-year increase of 83.24%.
Score
Financials
6.86
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.63
Operational Efficiency
10.00
Growth Potential
9.96
Shareholder Returns
8.24
Merck & Co Inc's Company Valuation
Currency: USD Updated: 2025-12-05The company’s current valuation score is 8.17, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 13.16, which is 6868.68% below the recent high of 917.15 and 19.02% above the recent low of 10.66.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 18/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-05The company’s current earnings forecast score is 7.60, which is lower than the Pharmaceuticals industry's average of 7.79. The average price target for Merck & Co Inc is 102.00, with a high of 139.00 and a low of 82.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
30
analysts
Buy
Current Rating
104.088
Target Price
+4.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
169
Total
6
Median
8
Average
Company name
Ratings
Analysts
Merck & Co Inc
MRK
30
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-05The company’s current price momentum score is 9.19, which is higher than the Pharmaceuticals industry's average of 7.40. Sideways: Currently, the stock price is trading between the resistance level at 108.63 and the support level at 88.03, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
101.148
Sell
MA10
101.902
Sell
MA20
96.980
Buy
MA50
90.313
Buy
MA100
86.398
Buy
MA200
84.825
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-05The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 81.35%, representing a quarter-over-quarter increase of 0.65%. The largest institutional shareholder is The Vanguard, holding a total of 250.94M shares, representing 10.11% of shares outstanding, with 0.99% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Wellington Management Company, LLP
Geode Capital Management, L.L.C.
Charles Schwab Investment Management, Inc.
Norges Bank Investment Management (NBIM)
Fidelity Management & Research Company LLC
BlackRock Asset Management Ireland Limited
1
2
Risk Assessment
Currency: USD Updated: 2025-12-05The company’s current risk assessment score is 9.40, which is higher than the Pharmaceuticals industry's average of 5.19. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.31
VaR
+2.09%
240-Day Maximum Drawdown
+27.27%
240-Day Volatility
+31.00%
Return
Best Daily Return
60 days
+7.39%
120 days
+7.39%
5 years
+8.37%
Worst Daily Return
60 days
-4.06%
120 days
-4.44%
5 years
-9.86%
Sharpe Ratio
60 days
+2.29
120 days
+1.56
5 years
+0.54
Risk Assessment
Maximum Drawdown
240 days
+27.27%
3 years
+44.74%
5 years
+44.74%
Return-to-Drawdown Ratio
240 days
+0.01
3 years
-0.06
5 years
+0.20
Skewness
240 days
-0.18
3 years
-0.39
5 years
-0.38
Volatility
Realised Volatility
240 days
+31.00%
5 years
+24.86%
Standardised True Range
240 days
+2.23%
5 years
+1.94%
Downside Risk-Adjusted Return
120 days
+295.02%
240 days
+295.02%
Maximum Daily Upside Volatility
60 days
+28.21%
Maximum Daily Downside Volatility
60 days
+17.47%
Liquidity
Average Turnover Rate
60 days
+0.56%
120 days
+0.60%
5 years
--
Turnover Deviation
20 days
-1.78%
60 days
+25.12%
120 days
+36.02%
Peer Comparison
Pharmaceuticals
Merck & Co Inc
MRK
8.36 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.73 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Vertex Pharmaceuticals Inc
VRTX
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Merck & Co Inc?
The TradingKey Stock Score provides a comprehensive assessment of Merck & Co Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Merck & Co Inc’s performance and outlook.
How do we generate the financial health score of Merck & Co Inc?
To generate the financial health score of Merck & Co Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Merck & Co Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Merck & Co Inc.
How do we generate the company valuation score of Merck & Co Inc?
To generate the company valuation score of Merck & Co Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Merck & Co Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Merck & Co Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Merck & Co Inc.
How do we generate the earnings forecast score of Merck & Co Inc?
To calculate the earnings forecast score of Merck & Co Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Merck & Co Inc’s future.
How do we generate the price momentum score of Merck & Co Inc?
When generating the price momentum score for Merck & Co Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Merck & Co Inc’s prices. A higher score indicates a more stable short-term price trend for Merck & Co Inc.
How do we generate the institutional confidence score of Merck & Co Inc?
To generate the institutional confidence score of Merck & Co Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Merck & Co Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Merck & Co Inc.
How do we generate the risk management score of Merck & Co Inc?
To assess the risk management score of Merck & Co Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Merck & Co Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Merck & Co Inc.
